We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Germany's new early benefit assessment for innovative pharmaceuticals

July 2011

Jörg Schickert and Andreas Schmitz bring clarity to some of the pressing questions surrounding the new system of assessment that replaced free drug pricing. There is confusion over the scope of the assessment, dossier obligations and the determination of the comparable therapy.

The team

Loading data